Evotix on Mission to Reduce Workplace Accidents in Europe and USA
2.11.2021 12:00:00 EET | Business Wire | Press release
Every year over 5,000 people are killed in workplace accidents in the US and EU – a number that’s risen in the US over the last ten years1 - and blue-collar workers in the US are five times as likely to have accidents as their white-collar counterparts2.
Evotix, an ESG business, formerly known as SHE Software and a world leader in environmental, health, safety and well-being software (EHS), announces today its mission to help organizations reduce these numbers through its investment in new staff, software, support and training services.
The business’ proposition is focussed on giving its clients ‘the confidence to transform’. For many organizations, changing the way they handle health and safety can be daunting because they don’t want to uproot established practices even if they are based on out-of-date processes and technologies. Evotix has the in-depth expertise in the latest technologies, especially those that improve and simplify the user experience, that enables organizations to implement the changes they – and their employees – need to make EHS simpler and safer.
Matthew Elson, CEO of Evotix, explains, “People, especially those that are less advantaged, have the right to work in a safer environment. Our business already helps protect the safety of over 3,000,000 employees worldwide and we’re determined to protect many, many more in the years to come.”
“Too many employees suffer workplace accidents or endure workplace related physical and mental health problems, causing issues not only for those individuals but for businesses and wider society. Many of these unfortunate situations would be avoidable if health and safety were embedded in the way the organization truly functions, supported by software featuring the latest user-friendly technologies. Engaging employees on safety issues needs to be simple, sustainable and tailored for the need of each individual organization and that’s what Evotix has been built to offer.”
“The introduction of the Evotix name is just one step on our journey. The SHE Software name has served us well during our early years, but we wanted a name that was both memorable and reflects our vision and evolved proposition. The Evotix name is a conflation of the key qualities that make us special – evolutionary technology, innovation and experience.”
Based in Chicago and London, over the past five years Evotix has grown by over 40% every year and now has over 130 staff across the US, Europe and Asia-Pacific. In the last two years the company has experienced its fastest ever growth and major customers include: GlaxoSmithKline, New Balance, Citrix and University of Cambridge.
SOLUTIONS FOR TOMORROW
Evotix focusses on promoting workplace health and safety by providing innovative and engaging technology that gets embedded in the everyday flow of activity.
Evotix provides a comprehensive solution covering all aspects of health and safety management.
The solution is online and mobile-first designed to be used quickly and easily on-the-spot. With Evotix, incidents can be reported and shared within minutes, actions can be tracked to completion and underlying trends can be analysed.
Understanding documents on a mobile phone can be challenging: many organizations have a percentage of their workforce who are illiterate. Evotix employs microlearning video and quizzes in the field to engage employees in understanding risk and following defined working methods.
Every organization is different so the software can be easily tailored and adapted as requirements evolve. Evotix is continually adding new innovation as technology evolves.
Matthew continues, “Our approach helps organizations and employees alike. For organizations, accidents and incidents are expensive, with direct costs including lost hours, damage, disruption and claims, and indirect costs including the impact on morale, reputation, stress and management distraction. “
“We believe employees deserve better. The risks associated with workplace accidents fall disproportionately on the most disadvantaged in society - gig economy workers, casual labourers. An organization that prioritises risk reduction for all its staff will perform better financially, operationally and reputationally. That’s where we are here to help.”
Dawn Hemmings at Citrix says, “I’ve partnered with Evotix for over five years at three different organisations. I have always valued them as a partner that cares as passionately about improving workplace safety as I do. That’s why, when I joined Citrix, one of my first actions was to call Evotix. We know that their vision to make EHS simpler, more intuitive and more engaging is aligned with ours and they have the capabilities and plans to make that vision a reality.”
ABOUT EVOTIX
Evotix is a global ESG technology company transforming the way employees engage in workplace health and safety. Its market leading solution, Assure, is used by more than 400 customers across a wide range of industries including manufacturing, food & drink, construction, utility services, transport & logistics, municipalities, healthcare, education and housing.
Customers include GlaxoSmithKline, New Balance, Citrix, Finsbury Foods, Eddie Stobart, Network Rail, Wacker Neuson, Euro Car Parts and University of Cambridge.
Evotix’s intuitive, mobile first application fosters worker participation, guiding frontline activities while capturing rich data to help prioritise safety and operational improvements and ensure compliance. Ease of deployment and resulting swift customer impact drive Evotix’s rapid multi-year growth.
Evotix has offices in Chicago, London, Manchester, Glasgow and Melbourne, and is backed by significant investors including Mercia Asset Management and Frog Capital.
1 Eurostat: Accidents at work; US Bureau of Labor Statistics: Fatal occupational injuries
2 US Bureau of Labor Statistics: Fatal occupational injuries
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005108/en/
Contact information
Giles Fraser at Brands2Life
+44 207 592 1200
info@brands2life.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
